Venus RemediesBOM:526953 -2.81%59 Days Payable is 86.62 as of Mar. 2026, which is 55% above its 10-year median of 55.76. GuruFocus rates BOM:526953 with a GF Score™ of 59/100 and a GF Value™ of ₹468.14 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 922 Drug Manufacturers companies, Venus Remedies ranks better than 53.15% on this metric.
The historical rank and industry rank for Venus Remedies's Days Payable or its related term are showing as below:
BOM:526953'
s Days Payable Range Over the Past 10 Years
Min: 42.35 Med: 55.76 Max: 96.77
Current: 95.26
During the past 13 years, Venus Remedies's highest Days Payable was 96.77. The lowest was 42.35. And the median was 55.76.
BOM:526953's Days Payable is ranked better than 53.15% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs BOM:526953: 95.26
Venus Remedies's Days Payable
increased
from Mar. 2025 (81.33) to Mar. 2026 (86.62).
It may suggest that Venus Remediesdelayed paying its suppliers.
Venus Remedies Days Payable Related Terms
Venus Remedies Days Payable Historical Data
* Premium members only.
The historical data trend for Venus Remedies's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Remedies Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's Days Payable distribution charts can be found below:
* The bar in red indicates where Venus Remedies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Venus Remedies's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Remedies (BOM:526953) has a Days Payable of 86.62 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Venus Remedies and its competitors. This is 55% above median its historical median of 55.76. Over the past decade, Venus Remedies' Days Payable has ranged from 42.35 to 96.77. According to the industry distribution chart, Venus Remedies ranks #432 out of 922 companies in the Drug Manufacturers industry, placing it in the top 46.9%.
Is Venus Remedies' Days Payable too high?
Venus Remedies' current Days Payable of 86.62 is 55% above median its 10-year median of 55.76. Over the past 10 years, this metric has ranged from a low of 42.35 to a high of 96.77. The Drug Manufacturers industry median Days Payable is 90.61. Venus Remedies' value of 86.62 is 4.4% below this industry median. Based on the distribution chart, Venus Remedies ranks #432 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Venus Remedies has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Venus Remedies ranks #432 out of 922 companies for Days Payable. This puts Venus Remedies in the upper half of its industry. The industry median Days Payable is 90.61. Venus Remedies' value of 86.62 is 4.4% below this benchmark. Historically, Venus Remedies' own Days Payable has ranged from 42.35 to 96.77 over the past decade. While the company's 10-year median is 55.76 vs. the industry median of 90.61, Venus Remedies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Remedies's current Days Payable of 86.62 is 4.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Venus Remedies and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Remedies's current Days Payable is 86.62, which is 55% above median its own 10-year median of 55.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹468.14, compared to a current price of ₹1,664.65 — trading 255.6% above its estimated fair value. The current Days Payable is 86.62, which is 55% above median its 10-year median of 55.76 and 4.4% below the Drug Manufacturers industry median of 90.61. Venus Remedies' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current Days Payable is 86.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Remedies (BOM:526953) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued.
The current stock price of ₹1,664.65 is trading 255.6% above its estimated GF Value™ of ₹468.14.
GuruFocus considers Venus Remedies to be Significantly Overvalued.
Key valuation signals for BOM:526953:
Days Payable: 86.62 (55% above median its 10-year median of 55.76)
GF Value™: ₹468.14 vs. price of ₹1,664.65 (255.6% above fair value)
Industry Position: 4.4% below the Drug Manufacturers median (#432 of 922)
No single metric tells the full story. See the BOM:526953 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
59GF Score
Get the complete analysis for BOM:526953
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526953 has been successfully added to your 
